J&J Q3 earnings beat but medtech sales missed due to Middle East conflict. Guidance raised but below Street. Orthopedics spinoff planned for mid-2027. Stock fell 4%+.
bearish 30 · impact 70
The orthopaedics segment generated $2.35 billion in Q3, part of the company's broader earnings release.
JNJ's board approved a $1.34 per share cash dividend for the fourth quarter, in line with the prior quarter's rate. The payment continues the company's long dividend history.
neutral 50 · impact 20
Johnson & Johnson posted $14.96 billion in U.S. sales for the third quarter.
neutral 50 · impact 30
Johnson & Johnson reported third-quarter net income of $210 million, according to a flash headline. Further details were not immediately available.
bearish 30 · impact 60
Phase 3 ICONIC-LEAD data at Fall Clinical Dermatology show >=72% of patients achieved PASI 90 and >=70% clear/almost clear skin at two years, with no new safety signals. 85% of responders regained response after retreatment.
bullish 70 · impact 40
